These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
55 related articles for article (PubMed ID: 15920492)
1. Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma. Hus M; Dmoszyńska A; Kocki J; Hus I; Jawniak D; Adamczyk-Cioch M; Grzasko N Leukemia; 2005 Aug; 19(8):1497-9. PubMed ID: 15920492 [No Abstract] [Full Text] [Related]
2. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Oliveira AM; Maria DA; Metzger M; Linardi C; Giorgi RR; Moura F; Martinez GA; Bydlowski SP; Novak EM Leuk Res; 2009 Jul; 33(7):970-3. PubMed ID: 18976811 [TBL] [Abstract][Full Text] [Related]
3. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma]. Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823 [TBL] [Abstract][Full Text] [Related]
4. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. Guglielmelli T; Bringhen S; Rrodhe S; Gay F; Cavallo F; Berruti A; Montefusco V; Piro E; Benevolo G; Petrucci MT; Caravita T; Offidani M; Corradini P; Boccadoro M; Saglio G; Palumbo A Eur J Cancer; 2011 Apr; 47(6):814-8. PubMed ID: 21334196 [TBL] [Abstract][Full Text] [Related]
5. [Role of thalidomide in the treatment of multiple myeloma]. Mikala G; Jákó J; Vályi-Nagy I Orv Hetil; 2001 Aug; 142(33):1789-98. PubMed ID: 11573449 [TBL] [Abstract][Full Text] [Related]
6. [Thalidomide with or without dexamethasone for refractory multiple myeloma]. Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ Therapie; 2002; 57(6):524-9. PubMed ID: 12666259 [TBL] [Abstract][Full Text] [Related]
7. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan. Wu SY; Yeh YM; Chen YP; Su WC; Chen TY Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703 [TBL] [Abstract][Full Text] [Related]
9. Thalidomide as anti-inflammatory therapy for multiple myeloma. Mehta P; Hussein M Leukemia; 2003 Nov; 17(11):2237-8; author reply 2238. PubMed ID: 12931217 [No Abstract] [Full Text] [Related]
10. Extramedullary progression of multiple myeloma under thalidomide therapy despite concomitant response of medullary disease. Candoni A; Simeone E; Fanin R Am J Hematol; 2008 Aug; 83(8):680-1. PubMed ID: 18459108 [No Abstract] [Full Text] [Related]
11. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. Ciepłuch H; Baran W; Hellmann A Med Sci Monit; 2002 Apr; 8(4):PI31-6. PubMed ID: 11951079 [TBL] [Abstract][Full Text] [Related]
12. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. Cibeira MT; Rosiñol L; Ramiro L; Esteve J; Torrebadell M; Bladé J Eur J Haematol; 2006 Dec; 77(6):486-92. PubMed ID: 16978238 [TBL] [Abstract][Full Text] [Related]
13. [Preliminary results of monotherapy with thalidomide in recurrent and treatment resistant cases of multiple myeloma]. Kyrcz-Krzemień S; Helbig G; Stella-Hołowiecka B; Hołowiecki J Wiad Lek; 2003; 56(5-6):227-32. PubMed ID: 14526479 [TBL] [Abstract][Full Text] [Related]
14. Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. Cibeira MT; de Larrea CF; Navarro A; Díaz T; Fuster D; Tovar N; Rosiñol L; Monzó M; Bladé J Leuk Res; 2011 Sep; 35(9):1178-83. PubMed ID: 21435719 [TBL] [Abstract][Full Text] [Related]
16. Extramedullary multiple myeloma escapes the effect of thalidomide. Rosiñol L; Cibeira MT; Bladé J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E Haematologica; 2004 Jul; 89(7):832-6. PubMed ID: 15257935 [TBL] [Abstract][Full Text] [Related]
17. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633 [TBL] [Abstract][Full Text] [Related]
18. Unusual myeloma relapse after thalidomide therapy: the dark side of the moon? Balleari E; Bruzzone A Leuk Res; 2009 Sep; 33(9):1164-5. PubMed ID: 19446332 [No Abstract] [Full Text] [Related]
19. Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China. Chen SL; Jiang B; Qiu LG; Yu L; Zhong YP; Gao W Anat Rec (Hoboken); 2010 Oct; 293(10):1679-84. PubMed ID: 20734318 [TBL] [Abstract][Full Text] [Related]